AmerisourceBergen Acquires Minority Interest in Profarma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AmerisourceBergen Acquires Minority Interest in Profarma


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 4
AmerisourceBergen reported that it has reached a definitive agreement to acquire a minority stake in Profarma, a pharmaceutical wholesaler in Brazil. In addition, AmerisourceBergen and Profarma will establish a joint venture for specialty distribution and services. The company expects to invest a total of approximately $100 million, and the transaction is expected to close in the June quarter of 2014.

AmerisourceBergen will purchase up to a 19.9% minority stake by offering $22.50 per share for shares offered in a primary offering by Profarma. This distribution joint venture will include Profarma’s existing specialty businesses and an equity investment from AmerisourceBergen. As a result, each company will own a 50% stake in the joint venture.

Source: AmerisourceBergen

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here